Terms: = Leukemia AND HMGA2, HMGI-C, 8091, ENSG00000149948, LIPO, HMGIC, BABL
69 results:
1. Study of mRNA of WT1, BAALC, EVI1, PRAME and hmga2 genes in whole blood samples.
Olkhovskiy IA; Gorbenko AS; Stolyar MA; Bakhtina VI; Mikhalev MA; Olkhovik TI; Sudarikov AB; Sidorova YS; Pospelova TI; Kolesnikova MA; Kaporskaya TS; Lyskova VA
Klin Lab Diagn; 2022 Oct; 67(10):613-620. PubMed ID: 36315178
[TBL] [Abstract] [Full Text] [Related]
2. hmga2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.
Moison C; Spinella JF; Chagraoui J; Lavallée VP; Lehnertz B; Thiollier C; Boivin I; Mayotte N; MacRae T; Marinier A; Hébert J; Sauvageau G
Blood Adv; 2022 Aug; 6(16):4793-4806. PubMed ID: 35797243
[TBL] [Abstract] [Full Text] [Related]
3. t(10;12)(q24;q15): A new cytogenetic marker in hematological malignancies.
Bernués M; González T; Corchete LA; Santos S; Durán MA; López-Andrade B; Riso LL; Martínez-Serra J; Ramos R; Iglesias J; Royo I; Rosell J
Cancer Genet; 2022 Jun; 264-265():60-65. PubMed ID: 35397254
[TBL] [Abstract] [Full Text] [Related]
4. TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells.
Sun H; Li Y; Wang X; Zhou X; Rong S; Liang D; Sun G; Cao H; Sun H; Wang R; Yan Y; Xie S; Sun Y
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35302171
[TBL] [Abstract] [Full Text] [Related]
5. The acidic domain of hmga2 and the domain's linker region are critical for driving self-renewal of hematopoietic stem cell.
Sun Y; Kubota S; Iimori M; Hamashima A; Murakami H; Bai J; Morii M; Yokomizo-Nakano T; Osato M; Araki K; Sashida G
Int J Hematol; 2022 Apr; 115(4):553-562. PubMed ID: 35067851
[TBL] [Abstract] [Full Text] [Related]
6. Critical role of the high mobility group A proteins in hematological malignancies.
De Martino M; Esposito F; Fusco A
Hematol Oncol; 2022 Feb; 40(1):2-10. PubMed ID: 34637548
[TBL] [Abstract] [Full Text] [Related]
7. Silencing of circTASP1 inhibits proliferation and induces apoptosis of acute myeloid leukaemia cells through modulating miR-515-5p/hmga2 axis.
Lin Y; Huang Y; Liang C; Xie S; Xie A
J Cell Mol Med; 2021 Aug; 25(15):7367-7380. PubMed ID: 34197029
[TBL] [Abstract] [Full Text] [Related]
8. [RNA Binding Protein RBM47 Inhibits the K562 Cell Proliferation by Regulating hmga2 mRNA Expression].
Lei T; Cui J; Hou JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):703-708. PubMed ID: 34105460
[TBL] [Abstract] [Full Text] [Related]
9. Overexpression of hmga2 activates Igf2bp2 and remodels transcriptional program of Tet2-deficient stem cells in myeloid transformation.
Bai J; Yokomizo-Nakano T; Kubota S; Sun Y; Kanai A; Iimori M; Harada H; Iwama A; Sashida G
Oncogene; 2021 Feb; 40(8):1531-1541. PubMed ID: 33452460
[TBL] [Abstract] [Full Text] [Related]
10. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
[TBL] [Abstract] [Full Text] [Related]
11. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
[TBL] [Abstract] [Full Text] [Related]
12. Leukocyte-Mimetic liposomes Penetrate Into Tumor Spheroids and Suppress Spheroid Growth by Encapsulated Doxorubicin.
Fukuta T; Yoshimi S; Kogure K
J Pharm Sci; 2021 Apr; 110(4):1701-1709. PubMed ID: 33129835
[TBL] [Abstract] [Full Text] [Related]
13. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA.
Muenchow A; Weller S; Hinterleitner C; Malenke E; Bugl S; Wirths S; Müller MR; Schulze-Osthoff K; Aulitzky WE; Kopp HG; Essmann F
Cell Death Dis; 2020 Aug; 11(8):701. PubMed ID: 32839432
[TBL] [Abstract] [Full Text] [Related]
14. [Development of DDS Actively to Overcome the Blood-brain Barrier in the Region of Ischemic Stroke].
Fukuta T; Kogure K
Yakugaku Zasshi; 2020; 140(8):1007-1012. PubMed ID: 32741858
[TBL] [Abstract] [Full Text] [Related]
15. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract] [Full Text] [Related]
16. The transcribed pseudogene RPSAP52 enhances the oncofetal hmga2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition.
Oliveira-Mateos C; Sánchez-Castillo A; Soler M; Obiols-Guardia A; Piñeyro D; Boque-Sastre R; Calleja-Cervantes ME; Castro de Moura M; Martínez-Cardús A; Rubio T; Pelletier J; Martínez-Iniesta M; Herrero-Martín D; Tirado OM; Gentilella A; Villanueva A; Esteller M; Farré L; Guil S
Nat Commun; 2019 Sep; 10(1):3979. PubMed ID: 31484926
[TBL] [Abstract] [Full Text] [Related]
17. Cost-Effectiveness Analysis of a hmga2 Prognostic Test for Acute Myeloid leukemia in a Canadian Setting.
Tremblay G; Rousseau B; Marquis M; Beaubois C; Sauvageau G; Hébert J
Appl Health Econ Health Policy; 2019 Dec; 17(6):827-839. PubMed ID: 31392669
[TBL] [Abstract] [Full Text] [Related]
18. Oncofetal hmga2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
Ahmed SM; Dröge P
Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
[TBL] [Abstract] [Full Text] [Related]
19. Circulating miR-29c, miR-30c, miR-193a-5p and miR-885-5p: Novel potential biomarkers for HTLV-1 infection diagnosis.
Fayyad-Kazan M; ElDirani R; Hamade E; El Majzoub R; Akl H; Bitar N; Fayyad-Kazan H; Badran B
Infect Genet Evol; 2019 Oct; 74():103938. PubMed ID: 31242452
[TBL] [Abstract] [Full Text] [Related]
20. Prediction of neuroblastoma cell response to treatment with natural or synthetic retinoids using selected protein biomarkers.
Dobrotkova V; Chlapek P; Jezova M; Adamkova K; Mazanek P; Sterba J; Veselska R
PLoS One; 2019; 14(6):e0218269. PubMed ID: 31188873
[TBL] [Abstract] [Full Text] [Related]
[Next]
